Connect with us

Technology

Commvault Announces Second Quarter Fiscal 2027 Financial Results

Published

on

Subscription revenue1 climbs +21% year over year to $269 million

Subscription annualized recurring revenue (ARR)1,2 reaches $1,104 million, up +20% year over year

Operating cash flow of $75 million, with free cash flow3 of $71 million

TINTON FALLS, N.J. , Oct. 27, 2026 /PRNewswire/ — Commvault (Nasdaq: CVLT) today announced its financial results for the fiscal second quarter ended September 30, 2026.

“With AI accelerating both innovation and risk in the enterprise, resilience continues to be a business imperative,” said Sanjay Mirchandani, President and CEO, Commvault. “Enterprises globally are increasingly turning to Commvault to stay resilient as they navigate more data, more identities, and greater complexity. We believe our strong Q2 results reflect that momentum, driving durable growth and shareholder value.”

Notes are contained at the end of this press release

Second Quarter Fiscal 2027 Highlights –

Subscription revenue was $269 million, up 21% year over year, inclusive of:SaaS revenue of $106 million, up 33% year over yearSubscription ARR grew to $1,104 million, up 20% year over yearConstant currency subscription ARR was $1,107 million, with fiscal Q2 net new subscription ARR of $51 million on a constant currency basis using March 31, 2026 spot ratesIncome from operations (EBIT) was $30 million, an operating margin of 9.7%Non-GAAP EBIT3 was $68 million, an operating margin of 21.9%Operating cash flow was $75 million, with free cash flow of $71 million

Recent Business Highlights –

Commvault introduced Commvault Active Directory Pre Recover, a new Identity Resilience innovation designed to reduce clean recovery of Active Directory from hours to minutes.Commvault expanded its FedRAMP High Authorized Cyber Resilience Services to managed services providers for protection and recovery of sensitive government data while supporting evolving federal cybersecurity requirements.Commvault integrated Threat Scan with Google Threat Intelligence to help organizations identify clean recovery points faster and accelerate recovery following cyberattacks.

Financial Outlook for Third Quarter and Full Year Fiscal 20274 –
We are providing the following guidance for the third quarter of fiscal year 2027:

Subscription revenue is expected to be between $293 million and $297 millionNon-GAAP EBIT margin is expected to be between 20.5% and 21.0%

We are providing the following updated guidance for the full fiscal year 2027:

Subscription revenue is expected to be between $1,127 million and $1,133 millionSubscription ARR is expected to be between $1,205 million and $1,215 millionNon-GAAP EBIT margin is expected to be between 21.0% and 21.5%Free cash flow is expected to be between $255 million and $265 millionDiluted shares outstanding are expected to be approximately 42 million

Financial Outlook for Full Year Fiscal 2027 Subscription ARR –
($ in millions)

FY’27 guidance as of June 30, 2026 (midpoint)

$        1,205

YTD currency impact using March 31, 2026 rates

(3)

Adjustment on revised annual outlook

8

FY’27 updated guidance as of September 30, 2026 (midpoint)

$        1,210

The above guidance metrics contemplate current macroeconomic conditions. These statements are forward-looking and made pursuant to the safe harbor provisions discussed in detail below. We do not undertake any obligation to update these forward-looking statements. Actual results may differ materially from anticipated results.

Conference Call Information
Commvault will host a conference call today, October 27, 2026 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss quarterly results. The live webcast and call dial-in numbers can be accessed by registering under the “News & Events” section of Commvault’s website at ir.commvault.com under the “Investor Events” heading. An archived webcast of this conference call will also be available following the call.

About Commvault
Commvault (Nasdaq: CVLT) delivers continuous recovery for the AI era. We help organizations stay ready for constant disruption by returning critical data, applications, identities, and AI systems to a clean, trusted state. Our purpose-built recovery solutions span cloud-native and hybrid environments, leveraging AI to enable resilience at enterprise scale.

Safe Harbor Statement
This press release may contain forward-looking statements, including statements regarding financial projections, which are subject to risks and uncertainties, such as those related to our restructuring plans, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of software products and related services, general economic conditions, outcome of litigation and others. For a discussion of these and other risks and uncertainties affecting Commvault’s business, see “Item 1A. Risk Factors” in our annual report on Form 10-K and “Item 1A. Risk Factors” in our most recent quarterly report on Form 10-Q. Statements regarding Commvault’s beliefs, plans, expectations or intentions regarding the future are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from anticipated results. Commvault does not undertake to update its forward-looking statements.

Overview
($ in thousands)

Q2’26

Q3’26

Q4’26

Q1’27

Q2’27

Revenue

Y/Y
Growth

Revenue

Y/Y
Growth

Revenue

Y/Y
Growth

Revenue

Y/Y
Growth

Revenue

Y/Y
Growth

Subscription:

Term-based license

$ 92,647

10 %

$          118,950

22 %

$          114,445

6 %

$          110,420

1 %

$          105,002

13 %

Term-based support

49,686

19 %

50,962

18 %

53,933

21 %

56,057

18 %

57,307

15 %

SaaS

80,018

61 %

87,379

44 %

93,139

43 %

100,550

39 %

106,203

33 %

Total subscription

222,351

26 %

257,291

28 %

261,517

20 %

267,027

16 %

268,512

21 %

Perpetual license

12,073

15 %

13,675

(17) %

10,129

(32) %

8,695

19 %

7,205

(40) %

Perpetual support

30,543

(15) %

29,309

(14) %

26,972

(15) %

25,475

(19) %

23,482

(23) %

Other services

11,221

2 %

13,557

25 %

13,074

26 %

12,934

(7) %

13,190

18 %

Total revenues

$          276,188

18 %

$          313,832

19 %

$          311,692

13 %

$          314,131

11 %

$          312,389

13 %

Constant Currency – Revenue
($ in thousands)

The constant currency impact is calculated using the average foreign exchange rates from the prior year period and applying these rates to foreign-denominated revenues in the current corresponding period. Commvault analyzes revenue growth on a constant currency basis in order to provide a comparable framework for assessing how the business performed excluding the effect of foreign currency fluctuations. The non-GAAP financial measures presented in this press release should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP.

Q2’26
Revenue as
Reported
(GAAP)

Q2’27
Revenue as
Reported
(GAAP)

Constant
Currency
Impact

% Change Y/Y
(GAAP)

% Change Y/Y
Constant
Currency

Subscription:

Term-based license

$       92,647

$     105,002

$          430

13 %

14 %

Term-based support

49,686

57,307

136

15 %

16 %

SaaS

80,018

106,203

(1)

33 %

33 %

Total subscription

222,351

268,512

565

21 %

21 %

Perpetual license

12,073

7,205

128

(40) %

(39) %

Perpetual support

30,543

23,482

255

(23) %

(22) %

Other services

11,221

13,190

(14)

18 %

17 %

Total

$     276,188

$     312,389

$          934

13 %

13 %

Disaggregation of Revenues
($ in thousands)

Our Americas region includes the United States, Canada, and Latin America. Our International region primarily includes Europe, the Middle East, Africa, Australia, India, and Southeast Asia.

Q2’26

Q3’26

Q4’26

Q1’27

Q2’27

Revenue

Y/Y
Growth

Revenue

Y/Y
Growth

Revenue

Y/Y
Growth

Revenue

Y/Y

Growth

Revenue

Y/Y
Growth

Americas

$          168,125

16 %

$          178,852

15 %

$          184,977

9 %

$          186,779

9 %

$          194,103

15 %

International

108,063

22 %

134,980

26 %

126,715

20 %

127,352

15 %

118,286

9 %

Total revenues

$          276,188

18 %

$          313,832

19 %

$          311,692

13 %

$          314,131

11 %

$          312,389

13 %

Subscription ARR and SaaS ARR
($ in thousands)

Q2’26

Q3’26

Q4’26

Q1’27

Q2’27

Subscription ARR

918,130

966,260

1,014,729

1,054,311

1,103,909

SaaS ARR

335,669

363,732

400,157

424,337

454,406

Constant Currency – Subscription ARR
($ in thousands)

Constant currency ARR is calculated using the foreign exchange spot rates from March 31, 2026 and applying these rates to foreign-denominated results in the periods presented.

Q1’27

Q2’27

Constant Currency Subscription ARR

Term-based Software ARR

$     630,864

$     651,402

SaaS ARR

424,879

455,387

Constant Currency Subscription ARR

$   1,055,743

$   1,106,789

Constant Currency Subscription Net New ARR

Term-based Software ARR

$      16,457

$      20,538

SaaS ARR

24,827

30,508

Constant Currency Subscription Net New ARR

$      41,284

$      51,046

Additional Financial Information

During the six months ended September 30, 2026, we repurchased approximately 906,000 shares of common stock for $119 millionWeighted average diluted shares outstanding were approximately 42 million for the period ended September 30, 2026Cash and cash equivalents totaled $897 million as of September 30, 2026Subscription net dollar retention rate5 was 113%

 

Commvault Systems, Inc.

 

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

Three Months Ended
September 30,

Six Months Ended
September 30,

2026

2025

2026

2025

Revenues:

  Subscription:

    Term-based license

$  105,002

$   92,647

$  215,422

$  201,929

    Term-based support

57,307

49,686

113,364

97,268

    Software-as-a-service

106,203

80,018

206,753

152,463

  Total subscription

268,512

222,351

535,539

451,660

  Perpetual license

7,205

12,073

15,900

19,408

  Perpetual support

23,482

30,543

48,957

61,982

  Other services

13,190

11,221

26,124

25,116

Total revenues

312,389

276,188

626,520

558,166

Cost of revenues:

  Term-based license

3,465

2,414

7,708

4,656

  Software-as-a-service

31,812

29,187

61,464

55,159

  Perpetual license

228

194

399

439

  Customer support

14,347

14,847

29,046

29,054

  Other services

9,018

8,402

17,862

16,513

Total cost of revenues

58,870

55,044

116,479

105,821

Gross margin

253,519

221,144

510,041

452,345

Operating expenses:

  Sales and marketing

135,529

122,240

275,324

244,719

  Research and development

42,292

39,859

81,834

79,921

  General and administrative

42,211

42,553

88,962

83,823

  Depreciation and amortization

2,786

2,572

5,105

5,179

  Restructuring

324

1,429

2,720

1,666

  Change in contingent consideration

—

—

—

(545)

Total operating expenses

223,142

208,653

453,945

414,763

Income from operations

30,377

12,491

56,096

37,582

Interest income

8,439

3,087

16,126

5,096

Interest expense

(1,482)

(637)

(2,955)

(915)

Other income, net

1,420

159

1,689

220

Income before income taxes

38,754

15,100

70,956

41,983

Income tax expense

9,643

370

20,706

3,757

Net income

$   29,111

$   14,730

$   50,250

$   38,226

Net income per common share:

  Basic

$      0.71

$      0.33

$      1.22

$      0.86

  Diluted

$      0.69

$      0.33

$      1.19

$      0.84

Weighted average common shares outstanding:

  Basic

41,261

44,406

41,303

44,366

  Diluted

42,221

45,195

42,057

45,264

 

Commvault Systems, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

September 30,

March 31,

2026

2026

ASSETS

Current assets:

  Cash and cash equivalents

$        897,250

$        899,987

  Trade accounts receivable, net

280,575

330,483

  Other current assets

62,295

56,040

Total current assets

1,240,120

1,286,510

Deferred tax assets, net

145,975

153,766

Property and equipment, net

13,479

9,750

Operating lease assets

35,956

34,920

Deferred commissions cost

113,437

103,892

Intangible assets, net

17,204

19,715

Goodwill

209,168

209,322

Other assets

99,723

68,430

Total assets

$     1,875,062

$     1,886,305

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

  Accounts payable

$             493

$             651

  Accrued liabilities

159,107

165,583

  Current portion of operating lease liabilities

7,443

6,963

  Deferred revenue

472,746

484,973

Total current liabilities

639,789

658,170

Convertible notes, net

882,989

880,863

Deferred revenue, less current portion

291,114

293,725

Deferred tax liabilities

1,134

1,565

Long-term operating lease liabilities

30,937

29,675

Other liabilities

16,565

14,813

Total stockholders’ equity

12,534

7,494

Total liabilities and stockholders’ equity

$     1,875,062

$     1,886,305

 

Commvault Systems, Inc.

 

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three Months Ended
September 30,

Six Months Ended
September 30,

2026

2025

2026

2025

Cash flows from operating activities

Net income

$   29,111

$   14,730

$   50,250

$   38,226

Adjustments to reconcile net income to net cash provided by operating
activities:

  Depreciation and amortization

2,786

2,572

5,105

5,179

  Amortization of debt issuance costs

1,166

409

2,330

494

  Amortization of deferred commissions costs

15,835

11,221

30,417

22,210

  Noncash stock-based compensation

35,780

32,224

71,070

62,404

  Noncash operating lease expense

2,008

1,774

3,924

3,410

  Noncash change in fair value of contingent consideration

—

—

—

(545)

  Noncash adjustment on headquarters sale leaseback

—

—

—

495

  Deferred income taxes

4,244

5,668

7,206

9,576

  Other

67

(138)

(115)

(199)

  Changes in operating assets and liabilities:

    Trade accounts receivable, net

(9,599)

20,258

49,115

24,006

    Other current assets and Other assets

(5,281)

(8,281)

(28,471)

(5,903)

    Deferred commissions cost

(18,923)

(13,712)

(40,222)

(28,784)

    Accounts payable

341

232

(165)

(88)

    Accrued liabilities

18,072

2,030

(8,209)

(45,230)

    Operating lease liabilities

(1,325)

(1,739)

(3,214)

(3,647)

    Deferred revenue

169

10,513

(12,139)

27,953

    Other liabilities

347

(992)

(414)

(1,107)

Net cash provided by operating activities

74,798

76,769

126,468

108,450

Cash flows from investing activities

Purchase of property and equipment

(3,932)

(3,187)

(4,501)

(5,066)

Purchase of investments

(144)

(482)

(8,039)

(6,626)

Proceeds from sale of headquarters, net

—

—

—

34,849

Business combination, net of cash acquired

—

(26,015)

—

(26,015)

Net cash used in investing activities

(4,076)

(29,684)

(12,540)

(2,858)

Cash flows from financing activities

Repurchase of common stock

(107,741)

(131,023)

(117,872)

(146,073)

Proceeds from stock-based compensation plans

6,585

6,974

6,585

6,974

Proceeds from issuance of convertible notes

—

900,000

—

900,000

Purchase of capped calls

—

(99,630)

—

(99,630)

Payment of debt issuance costs

—

(20,396)

—

(22,242)

Other

(113)

(18)

(188)

(30)

Net cash provided by (used in) financing activities

(101,269)

655,907

(111,475)

638,999

Effect of exchange rate changes on cash and cash equivalents

(2,040)

(2,671)

(5,190)

16,861

Net increase (decrease) in cash and cash equivalents

(32,587)

700,321

(2,737)

761,452

Cash and cash equivalents at beginning of period

929,837

363,234

899,987

302,103

Cash and cash equivalents at end of period

$  897,250

$  1,063,555

$  897,250

$  1,063,555

Supplemental disclosures of noncash activities

Operating lease liabilities arising from obtaining right-of-use assets

$    4,262

$    1,913

$    5,194

$   22,165

Debt issuance costs accrued but not paid, included in accrued liabilities

$        —

$       984

$        —

$       984

Share repurchases accrued but not paid, included in accrued liabilities

$    1,419

$        —

$    1,419

$        —

 

Commvault Systems, Inc.

 

Reconciliation of GAAP to Non-GAAP Financial Measures

 (In thousands, except per share data)

(Unaudited)

Three Months Ended
September 30,

Six Months Ended
September 30,

2026

2025

2026

2025

Non-GAAP financial measures and reconciliation:

  GAAP income from operations

$  30,377

$  12,491

$  56,096

$  37,582

    Noncash stock-based compensation6

35,680

31,813

70,405

61,918

    FICA and payroll tax expense related to stock-based compensation7

712

838

1,589

2,637

    Restructuring8

324

1,429

2,720

1,666

    Amortization of intangible assets9

1,255

1,140

2,511

2,211

    Business combination costs10

—

1,890

—

1,890

    Change in contingent consideration11

—

—

—

(545)

    Adjustment on headquarters sale leaseback12

—

—

—

495

    Non-recurring strategic pricing initiative costs13

—

—

6,500

—

    Other non-recurring charges14

—

1,805

—

1,805

  Non-GAAP income from operations

$  68,348

$  51,406

$ 139,821

$ 109,659

  GAAP net income

$  29,111

$  14,730

$  50,250

$  38,226

    Noncash stock-based compensation

35,680

31,813

70,405

61,918

    FICA and payroll tax expense related to stock-based compensation

712

838

1,589

2,637

    Restructuring

324

1,429

2,720

1,666

    Amortization of intangible assets

1,255

1,140

2,511

2,211

    Business combination costs

—

1,890

—

1,890

    Change in contingent consideration

—

—

—

(545)

    Adjustment on headquarters sale leaseback

—

—

—

495

    Non-recurring strategic pricing initiative costs

—

—

6,500

—

    Other non-recurring charges

—

1,805

—

1,805

    Non-GAAP provision for income taxes adjustment15

(8,771)

(12,593)

(16,417)

(23,617)

  Non-GAAP net income

$  58,311

$  41,052

$ 117,558

$  86,686

  GAAP diluted earnings per share

$     0.69

$     0.33

$     1.19

$     0.84

    Noncash stock-based compensation

0.85

0.70

1.67

1.37

    FICA and payroll tax expense related to stock-based compensation

0.02

0.02

0.04

0.06

    Restructuring

0.01

0.03

0.06

0.04

    Amortization of intangible assets

0.03

0.03

0.06

0.05

    Business combination costs

—

0.04

—

0.04

    Change in contingent consideration

—

—

—

(0.01)

    Adjustment on headquarters sale leaseback

—

—

—

0.01

    Non-recurring strategic pricing initiative costs

—

—

0.15

—

    Other non-recurring charges

—

0.04

—

0.04

    Non-GAAP provision for income taxes adjustment

(0.22)

(0.28)

(0.37)

(0.52)

  Non-GAAP diluted earnings per share

$    1.38

$    0.91

$    2.80

$    1.92

  GAAP diluted weighted average shares outstanding

42,221

45,195

42,057

45,264

Three Months Ended
September 30,

Six Months Ended
September 30,

2026

2025

2026

2025

Non-GAAP free cash flow reconciliation:

  GAAP net cash provided by operating activities

$  74,798

$  76,769

$ 126,468

$ 108,450

      Purchase of property and equipment

(3,932)

(3,187)

(4,501)

(5,066)

  Non-GAAP free cash flow

$  70,866

$  73,582

$ 121,967

$ 103,384

We monitor subscription annualized recurring revenue (“Subscription ARR”), SaaS ARR and subscription net dollar retention rate (“Subscription NRR”) to help evaluate the state of our business. We believe these metrics are material to investors to understand the growth and performance of our business, as they help normalize certain variable factors and provide a consistent view of our recurring revenue profile. Subscription ARR and SaaS ARR exclude non-recurring elements and reflect the annualized value of active contracts, while subscription NRR measures net expansion within our existing subscription customer base. Together, we believe these metrics offer meaningful insight into the health and trajectory of our recurring revenue streams. Commvault has also provided its Subscription ARR on a constant currency basis in order to provide a comparable framework for assessing how the business performed excluding the effect of foreign currency fluctuations. Total ARR, which also included the annualized maintenance contract on perpetual licenses, is no longer disclosed.

Use of Non-GAAP Financial Measures

We have provided in this press release the following non-GAAP financial measures: non-GAAP income from operations (EBIT), non-GAAP EBIT margin, non-GAAP net income, non-GAAP diluted earnings per share, and non-GAAP free cash flow. This financial information has not been prepared in accordance with GAAP. Commvault uses these non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. Commvault believes that the use of these non-GAAP financial measures, when used as a supplement to GAAP financial measures, provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing its financial results with other companies in Commvault’s industry, many of which present similar non-GAAP financial measures to the investment community. Commvault has also provided its revenues on a constant currency basis. We analyze revenue growth on a constant currency basis in order to provide a comparable framework for assessing how the business performed excluding the effect of foreign currency fluctuations.

All of these non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures, which are included in this press release.

Non-GAAP EBIT and non-GAAP EBIT margin. These non-GAAP financial measures exclude noncash stock-based compensation expense and additional Federal Insurance Contribution Act (FICA) and related payroll tax expense incurred by Commvault related to stock-based compensation. Commvault has also excluded restructuring costs, noncash amortization of intangible assets, business combination costs, the change in the estimated fair value of contingent consideration, adjustments from the sale and leaseback of headquarters, non-recurring strategic pricing initiative costs, and other non-recurring charges from its non-GAAP results. These adjustments are further discussed in the reconciliation of GAAP to non-GAAP financial measures. Commvault believes that these non-GAAP financial measures are useful metrics for management and investors because they compare Commvault’s core operating results over multiple periods. When evaluating the performance of Commvault’s operating results and developing short- and long-term plans, Commvault does not consider such expenses.

Although noncash stock-based compensation expense and the additional FICA and related payroll tax expense are necessary to attract and retain employees, Commvault places its primary emphasis on stockholder dilution as compared to the accounting charges related to such equity compensation plans. Commvault believes that providing non-GAAP financial measures that exclude noncash stock-based compensation expense and the additional FICA and related payroll tax expense allow investors to make meaningful comparisons between Commvault’s operating results and those of other companies.

There are a number of limitations related to the use of non-GAAP EBIT and non-GAAP EBIT margin.  The most significant limitation is that these non-GAAP financial measures exclude certain operating costs, primarily related to noncash stock-based compensation, which is of a recurring nature. Noncash stock-based compensation has been, and will continue to be for the foreseeable future, a significant recurring expense in Commvault’s operating results.  In addition, noncash stock-based compensation is an important part of Commvault’s employees’ compensation and can have a significant impact on their performance. The following table presents the stock-based compensation expense included in cost of revenues, sales and marketing, research and development and general and administrative ($ in thousands):

Three Months Ended
September 30,

Six Months Ended
September 30,

2026

2025

2026

2025

Cost of revenues

$    1,435

$    1,323

$    2,838

$    2,572

Sales and marketing

14,642

12,757

28,810

25,343

Research and development

8,034

7,752

16,318

14,822

General and administrative

11,569

9,981

22,439

19,181

Stock-based compensation expense

$   35,680

$   31,813

$   70,405

$   61,918

The table above excludes stock-based compensation expense related to the Company’s restructuring activities described below in Note 8.

The components that Commvault excludes in its non-GAAP financial measures may differ from the components that its peer companies exclude when they report their non-GAAP financial measures. Due to the limitations related to the use of non-GAAP measures, Commvault’s management assists investors by providing a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure. Commvault’s management uses non-GAAP financial measures only in addition to, and in conjunction with, results presented in accordance with GAAP.

Non-GAAP net income and non-GAAP diluted earnings per share (EPS).  In addition to the adjustments discussed in non-GAAP EBIT, non-GAAP net income and non-GAAP diluted EPS incorporates a non-GAAP effective tax rate of 24%.

Commvault anticipates that in any given period its non-GAAP tax rate may be either higher or lower than the GAAP tax rate as evidenced by historical fluctuations. Commvault defines its cash tax rate as the total amount of cash income taxes payable for the fiscal year divided by consolidated GAAP pre-tax income. Over time, Commvault believes its GAAP and cash tax rates will align.

Commvault considers non-GAAP net income and non-GAAP diluted EPS useful metrics for Commvault management and its investors for the same basic reasons that Commvault uses non-GAAP EBIT and non-GAAP EBIT margin. In addition, the same limitations as well as management actions to compensate for such limitations described above also apply to Commvault’s use of non-GAAP net income and non-GAAP diluted EPS.

Non-GAAP free cash flow.  Commvault defines this non-GAAP financial measure as net cash provided by operating activities less purchases of property and equipment. Commvault considers non-GAAP free cash flow a useful metric for Commvault management and its investors in evaluating Commvault’s ability to generate cash from its business operations. In addition, the same limitations as well as management actions to compensate for such limitations described above also apply to Commvault’s use of non-GAAP free cash flow.

Forward-looking non-GAAP measures.  In this press release, Commvault presents non-GAAP EBIT margin and free cash flow on a forward-looking basis. The most directly comparable GAAP measures are not accessible on a forward-looking basis without unreasonable efforts, because certain items that impact these GAAP measures, cannot be reasonably predicted or quantified. The probable significance of these items may be material, and as a result, the corresponding GAAP measures and a quantitative reconciliation to those GAAP measures are not available on a forward-looking basis.

Notes

Beginning in fiscal 2027, Customer support revenue has been further disaggregated between support associated with term-based software license arrangements (“Term-based support”) and support associated with perpetual software license arrangements (“Perpetual support”). Subscription revenue has also been reclassified to include Term-based support revenue, in addition to Term-based license and SaaS revenues. Prior period amounts have been reclassified to conform to the current period presentation. These reclassifications have no impact on total revenues, net income, or the underlying revenue recognition for these arrangements.

In addition, Subscription ARR has been reclassified to include enterprise support, further aligning Subscription ARR with Subscription revenue. Enterprise support consists of recurring customer success services that provide our customers with enhanced support, strategic guidance and dedicated technical expertise, and is included in Term-based support. Prior to fiscal 2027, enterprise support was included only in Total ARR. Prior period amounts have been reclassified to conform to the current period presentation. Total ARR, which also included the annualized maintenance contract on perpetual licenses, is no longer disclosed.

Subscription ARR represents the annualized value of all active contracts as of the end of a reporting period attributable to term‑based licenses, maintenance and support services associated with term license arrangements, enterprise support, SaaS subscriptions, and consumption‑based arrangements, calculated by dividing the total active contract value by the number of days in the contract term and multiplying the result by 365. For consumption-based arrangements on a pay as you go model without a fixed commitment, the applicable ARR is calculated by annualizing the revenue contractually expected to be received in a given month based on actual monthly usage from a prior month. SaaS ARR includes only the cloud‑hosted portion of subscription ARR and is calculated using the same methodology.   

These metrics should be viewed independently of GAAP revenue, deferred revenue and unbilled revenue and are not intended to be combined with or to replace those items. These metrics are not a forecast of future revenues. Management believes that reviewing these metrics, in addition to GAAP results, helps investors and financial analysts understand the value of Commvault’s recurring revenue streams presented on an annualized basis. There is no direct GAAP comparative to ARR.

A reconciliation of GAAP to non-GAAP results has been provided in the reconciliation of GAAP to non-GAAP financial measures included in this press release. An explanation of these measures is also included under the heading “Use of Non-GAAP Financial Measures.”

Commvault does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See “Forward-looking non-GAAP measures” for additional explanation.

Subscription net dollar retention rate (“Subscription NRR”) includes all contracts attributable to term‑based licenses, maintenance and support services associated with term license arrangements, enterprise support, SaaS subscriptions, and consumption‑based arrangements. Subscription NRR is calculated as the percentage of subscription ARR retained from existing customers at the start of an annual period after accounting for expansion revenue, churn, and downgrades, measured on an annualized basis using the trailing four quarter average. Acquired subscription ARR is excluded until the acquisition is fully integrated, which we generally expect to occur twelve months from the close date. We believe our subscription NRR offers valuable insight into the year-over-year expansion of our existing customer base, reflecting both increased utilization of current products and services as well as the adoption of additional offerings. There is no direct GAAP comparative to NRR.

Represents noncash stock-based compensation expense, exclusive of stock-based compensation expense related to Commvault’s restructuring activities described below in Note 8.

Represents additional FICA and related payroll tax expense incurred by Commvault related to stock-based compensation.

Restructuring charges relate to two plans designed to optimize our cost structure, enhance organizational agility, align resources with strategic priorities, and reorganize our business technology function. These initiatives include workforce reductions, technology transitions, office lease closures, and the exit of operations in certain jurisdictions. The related charges primarily consist of severance and associated employee termination costs, stock‑based compensation expense resulting from modification events, and office closure and exit charges. As of September 30, 2026, the majority of these costs have been incurred and the remaining activities are anticipated to be completed in fiscal 2027.

Represents noncash amortization of intangible assets.

These charges relate to acquisition and business development activities, including legal, accounting and advisory services. Management believes, when used as a supplement to GAAP results, that the exclusion of these costs will help investors and financial analysts understand Commvault’s operating results and underlying operational trends as compared to other periods.

Represents the change in the estimated fair value of the contingent consideration arrangement related to the acquisition of Appranix, Inc.

During the first quarter of fiscal 2026, we finalized the sale of our corporate headquarters and entered into a lease for a portion of the premises. These noncash charges represent accounting adjustments for a $1.3 million loss associated with the related lease terms and a $0.8 million adjustment to reflect the final sale price of the assets resulting in a net charge of $0.5 million recorded in general and administrative expense on the Consolidated Statements of Operations.

These charges relate to a non-routine business expense incurred during the first quarter of fiscal 2027 associated with strategic pricing and packaging initiatives. Given the non-recurring nature of the matter, these costs have been excluded from non-GAAP results as they are episodic in nature, directly tied to a discrete strategic initiative, and not reflective of ongoing operating performance.

These primarily legal and consulting expenses are related to our response in the second quarter of fiscal 2026 to a one-time security matter from the first quarter of fiscal 2026. Given the non-recurring nature of the matter, these costs have been excluded from non-GAAP results to provide a clearer view of ongoing operating performance.

The provision for income taxes is adjusted to reflect Commvault’s estimated non-GAAP effective tax rate of 24%.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/commvault-announces-second-quarter-fiscal-2027-financial-results-302919987.html

SOURCE COMMVAULT

Continue Reading

Technology

CHIME and ScaleHealth Announce Joint Venture to Expand Healthcare’s Innovation Ecosystem

Published

on

By

ScaleHealth, powered by CHIME, creates new pathways connecting healthcare leaders, innovators, technology partners, and investors to accelerate the future of digital health.

ANN ARBOR, Mich., Oct. 27, 2026 /PRNewswire/ — The College of Healthcare Information Management Executives (CHIME) today announced a strategic joint venture with ScaleHealth, Inc. to create ScaleHealth, powered by CHIME, LLC, a new innovation ecosystem designed to connect healthcare’s most pressing challenges with the innovators, leaders, organizations, and partners capable of solving them. By combining CHIME’s trusted digital health community with ScaleHealth’s expansive innovation ecosystem, the venture creates a unique environment where healthcare organizations, entrepreneurs, established technology companies, and investors can discover, connect, validate, and advance the ideas shaping the future of healthcare.

For 35 years, CHIME has evolved alongside the digital health leaders it serves. What began as a community centered on healthcare CIOs has grown into a global network of digital health leaders supported through education, events, research, policy initiatives, media platforms, executive collaboration, and professional communities. The creation of ScaleHealth, powered by CHIME represents the next chapter in that evolution, expanding CHIME’s ecosystem to include the innovators, entrepreneurs, and emerging technology companies helping define what comes next in healthcare.

As healthcare organizations face increasing pressure to improve outcomes, strengthen operations, address workforce challenges, improve cybersecurity, and realize the promise of emerging technologies including artificial intelligence, the need for stronger connections across the innovation ecosystem has never been greater. ScaleHealth, powered by CHIME was created to help build those connections.

“CHIME has spent 35 years bringing together the leaders responsible for solving healthcare’s most important technology and transformation challenges,” said Russ Branzell, President and CEO of CHIME. “As the pace of innovation continues to accelerate, we have an opportunity to expand that trusted community even further. ScaleHealth, powered by CHIME, extends our ecosystem to include entrepreneurs, innovators, investors, and emerging technology companies so that healthcare leaders can engage earlier, collaborate more effectively, and help shape the innovations that will define the future of healthcare.”

The opportunity emerged through CHIME’s growing innovation programming, particularly its Innovation Summit series, where healthcare leaders and technology companies increasingly expressed a desire to engage more directly with innovators and entrepreneurial organizations. At the same time, startups and growth-stage companies were seeking trusted pathways into healthcare and stronger connections to leaders who understand the industry’s real-world operational challenges.

“Healthcare has no shortage of innovation. The challenge is creating trusted pathways that connect innovators with the healthcare leaders who understand the industry’s most urgent problems,” said Taylor McPartland, CEO of ScaleHealth and leader of the new venture. “By combining ScaleHealth’s innovation ecosystem with CHIME’s trusted community of digital health leaders, we’re creating an environment where meaningful connections can lead to validation, partnership, and real-world impact. This is about bringing together everyone who has a role to play in the future of healthcare innovation and helping them move great ideas forward.”

Unlike traditional accelerators, startup showcases, or innovation marketplaces, ScaleHealth, powered by CHIME is designed as a trusted innovation ecosystem. Healthcare organizations bring forward meaningful challenges. Innovators and startups contribute cutting-edge ideas and technologies. Established technology organizations bring expertise, infrastructure, and scale. Investors provide capital and growth pathways. Together, these stakeholders create an environment where innovation can move from discovery and connection to validation, partnership, and measurable impact.

“Throughout its history, CHIME has grown by bringing the right people together around the challenges that matter most,” said Tressa Springmann, Senior Vice President and Chief Information and Digital Officer at LifeBridge Health and Chair of the CHIME Foundation Board of Directors. “Today, innovation is essential to every aspect of healthcare transformation. ScaleHealth, powered by CHIME extends that trusted community into a broader innovation ecosystem, creating new opportunities for healthcare leaders, entrepreneurs, technology partners, and investors to collaborate, learn from one another, and accelerate meaningful progress across healthcare.”

The venture reflects CHIME’s belief that the next era of digital health will be co-created by healthcare leaders, technology partners, entrepreneurs, investors, and innovators working together to solve the challenges that matter most. By creating a trusted environment for discovery, collaboration, validation, and advancement, ScaleHealth, powered by CHIME aims to become the connective layer between healthcare’s needs and the innovation being built to address them.

Read the full release here.

About CHIME
The College of Healthcare Information Management Executives (CHIME) is the leading professional organization for digital health executives and leaders. CHIME provides a trusted, collaborative environment where members and partners connect, share best practices, advance professional development, and advocate for the effective use of information and technology to improve health and care in the communities they serve. For more information, please visit chimecentral.org.

For media inquiries, please contact:

Contact

Calli Dretke
Executive Vice President & Chief Digital and Marketing Officer
CHIME                                                                                                           
734.412.6255
cdretke@dhinsights.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/chime-and-scalehealth-announce-joint-venture-to-expand-healthcares-innovation-ecosystem-302921260.html

SOURCE College of Healthcare Information Management Executives (CHIME)

Continue Reading

Technology

In HelloNation, Prenatal Imaging Expert Erika Lambright Explains Ultrasound Differences Between 2D, 3D, And 4D Imaging

Published

on

By

The article outlines how each type of pregnancy ultrasound supports fetal development and family understanding.

DENISON, Texas, Oct. 27, 2026 /PRNewswire/ — What is the difference between 2D, 3D, and 4D ultrasound imaging during pregnancy? HelloNation has published an article that clearly explains the differences between ultrasound and other prenatal imaging modalities and how each supports fetal development.

The HelloNation article explains that a 2d ultrasound is the most common form of prenatal imaging used during routine pregnancy ultrasound appointments. It produces flat, black-and-white images that allow medical providers to assess fetal development, monitor growth, and evaluate vital structures. The article notes that 2D ultrasound plays a central role in identifying potential concerns early and remains the foundation of prenatal diagnostic imaging.

According to the article, a 3d ultrasound builds on the same technology but creates a more detailed still image with depth. This form of prenatal imaging allows families to see clearer views of the baby’s face, hands, and feet. While 3d ultrasound can support certain medical evaluations, the article describes its primary value as helping parents better visualize fetal development in a more lifelike way.

The article further describes how a 4D ultrasound adds motion to the 3d ultrasound image. This allows families to view real-time video of the baby moving, stretching, or making facial expressions. The article explains that this type of pregnancy ultrasound creates a more engaging experience and helps strengthen the emotional connection, while still using the same safe, noninvasive prenatal imaging technology.

The HelloNation article emphasizes that understanding ultrasound differences helps families set clear expectations before imaging sessions. Each type of pregnancy ultrasound serves a distinct purpose. 2D ultrasound focuses on medical accuracy and fetal development monitoring, while 3D and 4D ultrasound provide enhanced visualization and connection. The article highlights that medical professionals typically rely on 2D ultrasound for diagnostic purposes, while 3D and 4D ultrasound are often optional.

The article also notes that several factors can affect the quality of prenatal imaging results. Baby position, gestational age, and fluid levels all play a role in how clearly images appear, especially during 3D and 4D ultrasound sessions. The article explains that providers often guide families on the best timing for ultrasound visits during pregnancy to improve image clarity and achieve better results.

Prenatal Imaging Experts emphasize through the article that learning about ultrasound differences can reduce uncertainty and help families feel more prepared. By understanding how each type of prenatal imaging contributes to monitoring fetal development, expectant parents can approach each pregnancy ultrasound appointment with clearer expectations.

The article concludes that while 2D ultrasound remains essential for medical care, the added perspectives of 3D and 4D ultrasound offer families a broader, more personal understanding of fetal development. Together, these forms of prenatal imaging provide both clinical insight and meaningful connection throughout pregnancy.

What Is the Difference Between 2D, 3D, and 4D Ultrasounds Explained Simply features insights from Erika Lambright, Prenatal Imaging Experts of Denison, Texas, in HelloNation.

About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused digital publications and innovative “edvertising” approach, HelloNation delivers expert-driven, good-news content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities. HelloNation maintains partnerships with the U.S. Conference of Mayors and the United States First Responders Association.

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-hellonation-prenatal-imaging-expert-erika-lambright-explains-ultrasound-differences-between-2d-3d-and-4d-imaging-302792440.html

SOURCE HelloNation

Continue Reading

Technology

Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain

Published

on

By

Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.1 

AACHEN, Germany, Oct. 27, 2026 /PRNewswire/ — Grünenthal, a global leader in pain management and research, today announced new data from the Phase III RISE trial (NCT04967664), evaluating Qutenza® versus control in people with post-surgical neuropathic pain. These data were shared today as late-breaking poster presentations at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand.

The trial (n=409) showed that Qutenza® achieved a statistically significantly greater reduction in average pain intensity (API) than the control treatment over weeks 2-12, meeting one of its pre-specified primary endpoints. When evaluating API at week 12 specifically, at the point when patients would typically return for retreatment, the numerical difference favoured Qutenza® but did not reach statistical significance. In the extension phase of the trial, in which up to 4 retreatments were allowed, Qutenza® achieved a statistically significantly greater reduction in API than the control treatment over weeks 2-42. Safety findings were consistent with previous Qutenza® trials and no new safety signals were observed. These data support the well-established efficacy and safety profile of Qutenza®.2,3

“Post-surgical neuropathic pain can be difficult to manage with current treatment options, and there is an urgent need for patient-centred, effective solutions. The RISE trial provides encouraging evidence that Qutenza® can deliver clinically meaningful and sustained pain reduction for up to 42 weeks, having shown a greater reduction in average pain intensity than the control,” said Prof. Patrice Forget, MD, PhD, FFPMRCA, Clinical Chair (full professor) in Anaesthesia, University of Aberdeen, and Honorary Consultant, NHS Grampian, Aberdeen, UK. “As IASP shines a global spotlight on neuropathic pain at this year’s congress, findings such as these are important to help improve outcomes for patients and reduce the burden of pain on families and healthcare systems.”

“Post-surgical neuropathic pain has been relatively understudied and continues to go under-recognised in clinical practice,” said Uli Brödl, Chief Scientific Officer, Grünenthal. “These results build on the robust body of evidence for Qutenza® and reinforce its potential to provide meaningful, long-lasting pain relief for people living with pain.”

Post-surgical neuropathic pain is a poorly recognised potential complication of surgery that can result in devastating outcomes. It affects millions of patients every year, with pain lasting for months or years post-procedure.1 It can also have a significant mental health impact, with patients reporting feeling extremely depressed or anxious, and having problems with daily activities.4

Qutenza® is already approved in Europe for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5 It is also approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.6

About the RISE trial2,3
The RISE (AV-001) trial is a Phase III multi-centre, randomised, double-blind, parallel-group trial to confirm the efficacy and safety of Qutenza 179mg cutaneous patch versus a low-dose capsaicin control patch in people with moderate to severe post-surgical neuropathic pain.

It included eligible adults with a 24-hour average pain intensity (API) score of 4 or more, a pain duration of 6 to 60 months after index surgery and a DN4 (Douleur Neuropathique 4) Interview score of 3 or more.

Participants were randomly assigned to receive treatment with either a 60-minute Qutenza patch (8%) or a low-dose capsaicin control patch (0.04%).

The trial had two primary endpoints:

Change in 24-hour API from baseline to the average score of the entire period between Week 2 and Week 12.Change in 24-hour API from baseline to the average score at Week 12.

The primary sponsor of the trial is Averitas Pharma, Inc., Grünenthal’s U.S. subsidiary.

About post-surgical neuropathic pain
Post-surgical neuropathic pain (PSNP) is defined as chronic pain with neuropathic characteristics that develops or increases after surgery and persists beyond the normal healing process. It is thought to arise, at least in part, from nerve injury and pain sensitisation associated with surgery.7

The signs and symptoms of peri- and post-surgical pain can vary based on the person and the severity of the injury caused in surgery. Reported symptoms include pain caused by stimuli that are normally painless (allodynia), abnormally increased sensitivity to pain (hyperalgesia), tingling, numbness, phantom pain and scar pain.8,9,10 

About Qutenza®
In Europe, Qutenza® (capsaicin) is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5

Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.6

Qutenza® is a topical TRPV1 agonist, designed to provide neuropathic pain relief for up to three months through defunctionalisation of nociceptors and nerve fibre regeneration.

About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion.

More information: www.grunenthal.com

Follow us on LinkedIn & Instagram

For further information, please contact:

Matt Crabb, Head of Global Communications (Interim) at Grünenthal

matt.crabb@grunenthal.com 

References

1 Gregory P & Settles K. Pract Pain Manag. 2013;13(9):1–6.
2 Wallace M et al. Efficacy of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
3 Wallace M et al. Safety and tolerability of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
4 Santos MP, Lemos F, Gomes J, Romao JM, Veiga D. Br J Pain 2024;18(1):42–56.
5 European Medicines Agency. Qutenza 179 mg cutaneous patch SmPC. Available at: https://www.medicines.org.uk/emc/product/573/smpc
6 US Food and Drug Administration. Qutenza® Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf
7 Correl D. F1000Res. 2017;6:1054.
8 Werner MU & Kongsgaard UE. Br J Anaesth. 2014;113(1):1–4.
9 Macrae WA. Br J Anaesth. 2008;101:77–86.
10 Searle RD & Simpson KH. Contin Educ Anaesth Crit Care Pain. 2010;10:12–14.

View original content:https://www.prnewswire.com/news-releases/grunenthal-presents-phase-iii-results-for-qutenza-in-post-surgical-neuropathic-pain-at-iasp-2026-world-congress-on-pain-302921015.html

SOURCE Grünenthal Group

Continue Reading

Trending